NHS Cancer Vaccine Launch Pad expanded to include trial for patients with advanced type of skin cancer

NHS Cancer Vaccine Launch Pad expanded to include trial for patients with advanced type of skin cancer Patients with an advanced type of skin melanoma in England will be given fast-track access to a “revolutionary” new cancer vaccine as part of an NHS trial. The vaccine, known as iSCIB1+ (ImmunoBody), helps the immune system recognise cancer cells and therefore better respond to immunotherapy treatment. Continue reading...

The UK regulator's clinical trial authorisation clears the path for a 550-patient registrational study of Scancell's lead immunotherapy iSCIB1+, with first survival data due in the second half of 2028.

The merged company will list on Nasdaq as SCLT and raise up to $89M to fund Phase 3 of its melanoma immunotherapy iSCIB1+.

Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.

Scancell Holdings Plc, iSCIB1+, advanced melanoma, melanoma immunotherapy, FDA Phase 3 clearance, cancer vaccines, ImmunoBody platform

Combining Scancell's melanoma drug iSCIB1+ with Yervoy and Opdivo significantly improved patient overall response rate.

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the British biotech to advance the next-generation cancer vaccine candidate rather than its older sibling.